Current P SYCHIATRY

Total Page:16

File Type:pdf, Size:1020Kb

Current P SYCHIATRY Current p SYCHIATRY When patients can’t sleep Practical guide to using Karl Doghramji, MD areful investigation can often Professor of psychiatry and human behavior reveal insomnia’s cause1—whether Director, Sleep Disorders Center a psychiatric or medical condition Thomas Jefferson University or poor sleep habits. Understanding why patients Philadelphia C can’t sleep is key to effective therapy. Acute and chronic sleep deprivation is associ- ated with measurable declines in daytime perfor- Tips to effective workup mance (Box). Some data even suggest that long- term sleeplessness increases the risk of new psychi- and treatment of insomnia— atric disorders—most notably major depression.3 whether acute or chronic PSYCHIATRIC DISORDERS AND INSOMNIA and associated with almost any Depression. Many depressed persons—up to 80%—experience insomnia, although no one psychiatric or medical disorder. sleep pattern seems typical.2 Depression may be associated with: • difficulties in falling asleep • interrupted nocturnal sleep • and early morning awakening. Anxiety disorders. Generalized anxiety disorder (GAD), social phobia, panic attacks, and post- traumatic stress disorder (PTSD) are all associat- ed with disrupted sleep. Patients with GAD 40 VOL. 2, NO. 5 / MAY 2003 and choosing hypnotic therapy VOL. 2, NO. 5 / MAY 2003 Current 41 p SYCHIATRY Insomnia Box have disrupted sleep patterns. These include The sleepless society: prolonged sleep latency, fragmented sleep with Chronic insomnia’s impact frequent arousals, decreased slow-wave sleep, variable REM latency, and decreased REM ne-half of adult Americans experience insomnia rebound after sleep deprivation. Despite Oduring their lives, and 10% report persistent sleep investigations going back to the 1950s, no spe- difficulties (longer than 2 weeks). Individuals who cific link between REM sleep and psychosis complain of insomnia report: has been found.6 Interestingly, increases in • daytime drowsiness REM sleep time and REM activity have been • diminished memory and concentration associated with an increased risk of suicide in • depression patients with schizophrenia.7 • strained relationships Adjustment sleep disorder. Acute emotional • increased risk of accidents stressors—such as bereavement, job loss, or • impaired job performance. hospitalization—often cause adjustment sleep disorder. Symptoms typically remit Despite these complaints, a surprising 70% of those with insomnia never seek medical help. Only 6% soon after the stressors abate, so this tran- visit their physicians specifically for insomnia, and sient insomnia usually lasts a few days to a 24% address sleep difficulty as a secondary complaint. few weeks. Treatment with behavioral ther- Many (40%) self-medicate with over-the-counter sleep apies and hypnotics8 is warranted if: aids or alcohol.2 • sleepiness and fatigue interfere with Insomnia becomes more frequent with aging, daytime functioning associated with increased rates of medical and • a pattern of recurring episodes psychiatric illness and an age-related deterioration develops.9 in the brain’s sleep-generating processes.3 Psychophysiologic insomnia. Once initiat- ed—regardless of cause—insomnia may persist well after its precipitating factors experience prolonged sleep latency (time needed resolve. Thus, short-term insomnia may develop to fall asleep after lights out) and fragmented into long-term, chronic difficulty with recurring sleep, similar to those with primary insomnia. episodes or a constant, daily pattern of insomnia. Subjective sleep quality may be impaired in Sufferers often spend hours in bed awake focused patients with social phobia. Some patients expe- upon—and brooding over—their sleeplessness. rience panic symptoms while sleeping, possibly in which in turn further aggravates their insomnia. association with mild hypercapnia. Patients with Adjustment sleep disorder and psychophysio- sleep panic attacks tend to have earlier onset of logic insomnia are included within DSM-IV’s panic disorder and a higher likelihood of comor- term “primary insomnia.” bid mood and other anxiety disorders.4 In patients with PTSD, disturbed sleep con- OTHER CAUSES OF INSOMNIA tinuity and increased REM phasic activity—such Medications that may affect sleep quality include as eye movements—are directly correlated with antidepressants (Table 1),10,11 antihypertensives, severity of PTSD symptoms. Nightmares and antineoplastic agents, bronchodilators, stimulants, disturbed REM sleep are hypothesized hallmarks corticosteroids, decongestants, diuretics, hista- of PTSD.5 mine-2 receptor blockers, and smoking cessation Schizophrenia. Patients with schizophrenia often aids. 42 Current VOL. 2, NO. 5 / MAY 2003 p SYCHIATRY Current p SYCHIATRY Recreational drugs, such as Table 1 cocaine, often cause insomnia. Antidepressants’ effects on sleep and wakefulness Hypnotics and anxiolytics can cause insomnia following long- Activating Bupropion, protriptyline, most selective serotonin term use and during withdrawal. agents reuptake inhibitors, venlafaxine, monoamine Other disorders known to dis- oxidase inhibitors turb sleep include periodic limb Sedating Amitriptyline, doxepin, trimipramine, nefazodone, movement disorder (PLMD), agents trazodone, mirtazapine restless legs syndrome (RLS), Neutral Citalopram, escitalopram sleep apnea syndrome, disrupted agents circadian rhythms (as with travel or shift work), cardiopulmonary disorders, chronic pain, diabetes, hyperthyroidism, hot flashes associated with Carefully review sleep patterns on weekdays and menopause, seizures, dementia, and Parkinson’s weekends, bedtime habits, sleep hygiene habits, disease, to name a few. and substance and medication use. Sleep clinic referrals. Consider an evaluation by a WORKUP OF SLEEP COMPLAINTS sleep disorders center when: Acute. Most short-term insomnias—lasting a few • the diagnosis remains unclear weeks or less—are caused by situational stressors, • or treatment of the presumed conditions circadian rhythm alterations, and sleep hygiene fails after a reasonable time violations. A logical initial approach, therefore, is to combine sleep hygiene measures with support- BEHAVIORAL TREATMENTS ive psychotherapy. Hypnotic agents may be con- Behavioral treatments—with or without hyp- sidered for apparent daytime consequences—such notics—are appropriate for a wide variety of as sleepiness and occupational impair- insomnia complaints, includ- ment—or if the insomnia seems ing adjustment sleep disorder, to be escalating. psychophysiologic insomnia, and Chronic. For longer-term insom- Behavioral measures depression. Behavioral measures may nias—lasting more than a few take longer to take longer to implement than drug ther- weeks—consider a more thor- implement but last apy, but their effects have been shown to ough evaluation, including longer than drug last longer in patients with primary insom- medical and psychiatric history, therapy nia. In many cases, it may be useful to start physical examination, and men- with both hypnotic and behavioral treat- tal status examination. Inquire ments and withdraw the hypnotic after about cardinal symptoms of disorders associated behavioral measures take effect. with insomnia, including: Sleep hygiene. Many individuals unknowingly • snoring or breathing pauses during sleep engage in habitual behaviors that impair sleep. (sleep apnea syndrome) Those with insomnia, for example, often try to • restlessness or twitching in the lower compensate for lost sleep by staying in bed later extremities (PLMS/RLS). in the morning or by napping, which further Question the bed partner, who may be more fragment nocturnal sleep. Advise these patients to aware of such symptoms than the patient. adhere to a regular awakening time—regardless continued on page 47 VOL. 2, NO. 5 / MAY 2003 43 Current p SYCHIATRY continued from page 43 of how long they slept the night before— Table 2 and to avoid naps. Other tips for getting a How to get a good night’s sleep good night’s sleep are outlined in Table 2.12 Caffeine has a plasma half-life of 3 to • Maintain a regular waking time, regardless of 7 hours, although individual sensitivity amount of sleep the night before varies widely and caffeine’s erratic • Avoid excessive time in bed absorption can prolong its effects. Advise • Avoid naps, except if a shift worker or elderly patients with insomnia to avoid caffeine- • Spend time in bright light while awake containing beverages—including coffee, tea, and soft drinks—after noon. • Use the bed only for sleeping and sex Relaxation training. Muscle tension can be • Avoid nicotine, caffeine, and alcohol reduced through electromyography • Exercise regularly early in the day (EMG) biofeedback, abdominal breath- • Do something relaxing before bedtime ing exercises, or progressive muscle relax- • Don’t watch the clock ation techniques, among others. • Eat a light snack before bedtime if hungry Relaxation training is usually effective within a few weeks. Psychotherapy. Cognitive-behavioral therapy can help identify and dispel tension-pro- dard textbooks but is clearly needed by a small ducing thoughts that are disrupting sleep, such as number of patients with chronic insomnia. In preoccupation with unpleasant work experiences these cases, carefully monitor for tolerance, as or school examinations. Reassurance may help manifested by dosage patients overcome fears about escalation. Long-term hyp- sleeplessness; suggest that patients notic treatment is not suitable deal with anxiety-producing Prolonged hypnotic for patients
Recommended publications
  • Molecular Mechanisms Underlying Estrogen-Induced Micronucleus Formation in Breast Cancer Cells
    M o l e c u l a r M e c h a n is m s U n d e r l y in g E s t r o g e n-In d u c e d M icronucleus F o r m a t io n in B r e a st C a n c e r C ells Submitted by Alena KABIL For the degree of Doctor of Philosophy The School of Pharmacy, University of Lonodon April, 2008 ProQuest Number: 10104729 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10104729 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Za moje najdraze roditelje ABSTRACT Molecular mechanisms underlying estrogen-induced micronucleus formation in breast cancer cells Aneuploidy, or numerical changes of chromosomes, has been documented in almost all solid tumours and the frequency of micronucleus formation is commonly taken as a biomarker of aneuploidy. An increasing number of observations suggest that exposure to physiologically relevant concentrations of steroidal estrogens gives rise to chromosomal impairments in estrogen receptor competent cells.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Association of Selective Serotonin Reuptake Inhibitors with the Risk for Spontaneous Intracranial Hemorrhage
    Supplementary Online Content Renoux C, Vahey S, Dell’Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published online December 5, 2016. doi:10.1001/jamaneurol.2016.4529 eMethods 1. List of Antidepressants for Cohort Entry eMethods 2. List of Antidepressants According to the Degree of Serotonin Reuptake Inhibition eMethods 3. Potential Confounding Variables Included in Multivariate Models eMethods 4. Sensitivity Analyses eFigure. Flowchart of Incident Antidepressant (AD) Cohort Definition and Case- Control Selection eTable 1. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 2. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of SSRIs Relative to TCAs eTable 3. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of SSRIs Relative to TCAs. eTable 4. Crude and Adjusted Rate Ratios of Intracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 5. Crude and Adjusted Rate Ratios of Subarachnoid Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak eTable 6. Crude and Adjusted Rate Ratios of Intracranial Extracerebral Hemorrhage Associated With Current Use of Antidepressants With Strong Degree of Inhibition of Serotonin Reuptake Relative to Weak This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 eMethods 1.
    [Show full text]
  • Pyrazolopyrimidine Jak Inhibitor Compounds And
    (19) TZZ ¥Z_T (11) EP 2 348 860 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A01N 43/90 (2006.01) A61K 31/519 (2006.01) 27.05.2015 Bulletin 2015/22 C07D 487/04 (2006.01) A61P 35/00 (2006.01) (21) Application number: 09824234.0 (86) International application number: PCT/US2009/063014 (22) Date of filing: 02.11.2009 (87) International publication number: WO 2010/051549 (06.05.2010 Gazette 2010/18) (54) PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS PYRAZOLOPYRIMIDIN-JAK-HEMMER-VERBINDUNGEN UND ENTSPRECHENDE VERFAHREN COMPOSÉS INHIBITEURS DE JAK À LA PYRAZOLOPYRIMIDINE ET PROCÉDÉS (84) Designated Contracting States: • MAGNUSON, Steven R. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Dublin HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL California 94568 (US) PT RO SE SI SK SM TR • PASTOR, Richard Designated Extension States: San Francisco AL BA RS California 94102 (US) • RAWSON, Thomas E. (30) Priority: 31.10.2008 US 110497 Mountain View California 94043 (US) (43) Date of publication of application: • ZHOU, Aihe 03.08.2011 Bulletin 2011/31 San Jose California 95129 (US) (60) Divisional application: • ZHU, Bing-Yan 15163226.2 Palo Alto California 94303 (US) (73) Proprietor: Genentech, Inc. South San Francisco, CA 94080 (US) (74) Representative: Bailey, Sam Rogerson et al Mewburn Ellis LLP (72) Inventors: 33 Gutter Lane • BLANEY, Jeffrey London South San Francisco, California 94080 (US) EC2V 8AS (GB) • GIBBONS, Paul A. South San Francisco, California 94080 (US) (56) References cited: • HANAN, Emily WO-A1-2007/013673 WO-A2-2004/052315 South San Francisco, California 94080 (US) WO-A2-2008/004698 US-A1- 2007 082 902 • LYSSIKATOS, Joseph P.
    [Show full text]
  • Report and Evidence Tables
    Drug Class Review on Second Generation Antidepressants Final Report Update 1 July 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Gerald Gartlehner, M.D., M.P.H. Richard A. Hansen, Ph.D. Leila Kahwati, M.D., M.P.H. Kathleen N. Lohr, Ph.D. Bradley Gaynes, M.D., M.P.H. Tim Carey, M.D., M.P.H. RTI-UNC Evidence-based Practice Center Cecil G. Sheps Center for Health Services Research University of North Carolina at Chapel Hill 725 Airport Road, CB# 7590 Chapel Hill, NC 27599-7590 Tim Carey, M.D., M.P.H., Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved Final Report Update 1 Drug Effectiveness Review Project Table of Contents Introduction........................................................................................................................ 4 Overview................................................................................................................. 4 Scope and Key Questions ....................................................................................... 7 Methods..............................................................................................................................
    [Show full text]
  • Changing Medications Usually Is Not Complicated, but Problems Can Arise
    Changing medications usually is not complicated, but problems can arise— especially with shorter half-life agents Discontinuing an antidepressant? Tapering tips to ease distressing symptoms David J. Muzina, MD ost psychiatrists have encountered patients who report dis- Vice president and national practice leader tressing symptoms when they have forgotten to take their for neurosciences Medco Health Solutions Mantidepressant for a few days or during changes in the medi- Fort Worth, TX cation regimen. A discontinuation syndrome can occur with almost any antidepressant, highlighting the need to slowly taper these medi- cations when discontinuation is part of a treatment plan. This article discusses antidepressant discontinuation syndrome (ADS) in a patient who experienced substantial distress after a rapid anti- depressant taper in preparation for electroconvulsive therapy (ECT). My goal is to raise awareness of ADS, promote early detection of the syn- drome, and address proper prevention and management strategies. CASE REPORT Feeling ‘worse than ever’ Mr. J, a 32-year-old tax accountant, is hospitalized for a major depressive episode (MDE) associated with deteriorating function and suicidal ide- ation. This second lifetime MDE started 8 months before his admission to an inpatient mood disorders unit. Mr. J initially was treated with fluoxetine, up to 40 mg/d across 14 weeks, with good tolerability but no significant benefit. His psychiatrist switched Mr. J to bupropion but stopped it after 4 weeks because of side effects— including headaches, insomnia, and tremor—and limited antidepressant benefit. Venlafaxine XR was initiated next, at 150 mg/d within the first 2 ES ag weeks, increased to 225 mg/d at week 6, then titrated to 300 mg/d at week 10.
    [Show full text]
  • Psychedelic Drugs
    108 PSYCHEDELIC DRUGS HENRY DAVID ABRAHAM UNA D. MCCANN GEORGE A. RICAURTE As defined in this chapter, the term psychedelic drugs includes 14.1%, and 7.2% of Danes reported the use of hallucino- both classic hallucinogens [i.e., indolalkylamines and phe- genic mushrooms (3). nylalkylamines, such as lysergic acid diethylamide (LSD) and In the United States, a survey of 633 undergraduates mescaline, respectively], ‘‘dissociative’’ drugs [i.e., arylcyclo- found that 23.8% had experimented with hallucinogenic hexamines, such as phencyclidine (PCP) and ketamine], and mushrooms, and 16.3% had had experience with LSD. substituted amphetamine analogues [i.e., phenylpropano- Among LSD users, 6.6% reported problems associated with lamines, such as 3,4-methylenedioxymethamphetamine LSD (Abraham and Koob, unpublished data). Of this group, (MDMA, ‘‘ecstasy’’)]. The use of psychedelic drugs dates 46.9% reported symptoms of hallucinogen persisting per- from the dawn of recorded history and continues today. ception disorder (HPPD), 37.5% described alcohol depen- Indeed, in Western culture, their use appears to be on the dence, 25% major depression, 18.8% persisting delusions, rise. Despite the longstanding popularity of psychedelic 15.6% panic attacks, and 12.5% auditory hallucinations. drugs, controlled research evaluating their effects in humans LSD use is most likely to occur between the ages of 18 and has been surprisingly scant, and data from preclinical studies 25. Use is more common in male Caucasians and Hispanics. have been largely limited to the last several decades. This Of note is that although the parents of LSD users tend to chapter reviews preclinical and clinical research involving be of a higher socioeconomic status, the users themselves indolalkylamines, arylcyclohexamines, and substituted am- exhibit an inverse relationship between LSD use and educa- phetamines, for which LSD, PCP, and MDMA are used as tional achievement (4).
    [Show full text]
  • Tcas Versus Placebo - New Studies in the Guideline Update
    TCAs versus placebo - new studies in the guideline update Comparisons Included in this Clinical Question Amitriptyline vs placebo Clomipramine vs placebo Dosulepin (dothiepin) vs placebo AMSTERDAM2003A LARSEN1989 FERGUSON1994B BAKISH1992B PECKNOLD1976B ITIL1993 BAKISH1992C RAMPELLO1991 MINDHAM1991 BREMNER1995 THOMPSON2001B CLAGHORN1983 CLAGHORN1983B FEIGHNER1979 GELENBERG1990 GEORGOTAS1982A GOLDBERG1980 HICKS1988 HOLLYMAN1988 HORMAZABAL1985 HOSCHL1989 KLIESER1988 LAAKMAN1995 LAPIERRE1991 LYDIARD1997 MYNORSWALLIS1995 MYNORSWALLIS1997 REIMHERR1990 RICKELS1982D RICKELS1985 RICKELS1991 ROFFMAN1982 ROWAN1982 SMITH1990 SPRING1992 STASSEN1993 WILCOX1994 16 Imipramine vs placebo BARGESCHAAPVELD2002 BEASLEY1991B BOYER1996A BYERLEY1988 CASSANO1986 CASSANO1996 CLAGHORN1996A COHN1984 COHN1985 COHN1990A COHN1992 COHN1996 DOMINGUEZ1981 DOMINGUEZ1985 DUNBAR1991 ELKIN1989 ENTSUAH1994 ESCOBAR1980 FABRE1980 FABRE1992 FABRE1996 FEIGER1996A FEIGHNER1980 FEIGHNER1982 FEIGHNER1983A FEIGHNER1983B FEIGHNER1989 FEIGHNER1989A FEIGHNER1989B FEIGHNER1989C FEIGHNER1992B FEIGHNER1993 FONTAINE1994 GELENBERG2002 GERNER1980B HAYES1983 ITIL1983A KASPER1995B KELLAMS1979 LAIRD1993 LAPIERRE1987 LECRUBIER1997B LIPMAN1986 LYDIARD1989 MARCH1990 17 MARKOWITZ1985 MENDELS1986 MERIDETH1983 Nortriptyline vs placebo NANDI1976 GEORGOTAS1986A NORTON1984 KATZ1990 PEDERSEN2002 NAIR1995 PESELOW1989 WHITE1984A PESELOW1989B PHILIPP1999 QUITKIN1989 RICKELS1981 RICKELS1982A RICKELS1987 SCHWEIZER1994 SCHWEIZER1998 SHRIVASTAVA1992 SILVERSTONE1994 SMALL1981 UCHA1990 VERSIANI1989 VERSIANI1990
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Providers | Medications for Depression
    Medications for Depression Antidepressants alter the concentrations of one or more key neurotransmitters in the brain, namely norepinephrine, serotonin, and dopamine. As depression may be a presenting symptom of a mixed manic episode, it is important to adequately screen patients with depressive symptoms to determine if they are at risk of bipolar disorder. All patients should also be monitored with regards to mental status for depression, suicidal ideation, anxiety, social functioning, mania, panic attacks, or other unusual changes in behavior. All antidepressants carry a black box warning of increased risk of suicidal thinking and behavior in children and adolescents, particularly in the first few months of therapy. MAOIs are contraindicated with all other classes of antidepressants and should not be used in combination. Common side effects often improve within the first two weeks of treatment. A low starting dose might help increase tolerance and adherence. DRUG CATEGORY MEDICATION COMMON SIDE EFFECTS MONITORING PARAMETERS ADDITIONAL COMMENTS Selective Serotonin .Citalopram (IR, Liq)* .GI: effects are common (nausea, xerostomia, diarrhea) .Weight and BMI .Comparable to TCAs in efficacy, but are markedly safer and better tolerated Reuptake Inhibitors .Escitalopram (IR, Liq) .Sexual dysfunction: in both men & women .Signs/symptoms of serotonin syndrome .SSRIs differ from each other with respect to their degree of selectivity for the serotonin (SSRIs) .Fluoxetine (IR, Liq ) .Hematologic: Impaired platelet aggregation/bleeding .Electrolytes,
    [Show full text]
  • Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period
    Supplementary Online Content Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naïve patients in the postoperative period. JAMA Intern Med. Published online July 11, 2016. doi:10.1001/jamainternmed.2016.3298. eTable 1. List of CPT Codes eFigure. Sample Construction Flow Chart eTable 2. List of Drug Classes eTable 3. List of Medical Comorbidities and ICD-9 Codes eTable 4. Sample Summary Characteristics, by procedure eTable 5. Risk Factors for Chronic Opioid Use Following Surgery Among Opioid Naïve Patients This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 1. List of CPT codes CPT Codes Total Knee Arthroplasty1 27447 Total Hip Arthroplasty1 27130 Laparoscopic Cholecystectomy2 47562, 47563, 47564 Open Cholecystectomy3 47600, 47605, 47610 Laparoscopic Appendectomy4 44970, 44979 Open Appendectomy5 44950, 44960 Cesarean Section6 59510, 59514, 59515 FESS7 31237, 31240, 31254, 31255, 31256, 31267, 31276, 31287, 31288 Cataract Surgery8 66982, 66983, 66984 TURP9 52601, 52612, 52614 Simple Mastectomy10‐12 19301, 19302, 19303, 19180 © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eFigure. Sample Construction Flow Chart © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 2.
    [Show full text]
  • Antidepressant Medications: U.S. Food and Drug Administration
    Antidepressant Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults The therapeutic dosing recommendations for antidepressant medications are based on U.S. Food and Drug Administration (FDA)-approved product labeling. Nevertheless, the dosing regimen is adjusted according to a patient’s individual response to pharmacotherapy. The FDA-approved indications and dosages for the use of antidepressant medications in adults are provided in this table. Some of the antidepressant medications are FDA-approved for the treatment of or as adjunct therapy for Parkinson’s disease. This indication is not discussed in this document because of its very specific focus and individualized treatment regimens. All of the antidepressant medications listed are for oral administration unless otherwise stated. Information on the generic availability of antidepressant medications can be found by searching the Electronic Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm on the FDA website. Generic Medication Indication Initial Dose Maximum Dose Other Information Availability amitriptyline[1] depression Outpatients: Outpatients: Outpatients may be initiated at 50 mg Yes 75 mg per day; 150 mg per day; to 100 mg once a day at bedtime. Dose Hospitalized patients: Hospitalized patients: increases should be made gradually by 100 mg per day 300 mg per day 25 mg to 50 mg as necessary, preferably in the late afternoon or evening. Lower doses are recommended for elderly patients. Take in divided doses. amoxapine[2] depression 50 mg 2 or 3 times a day 400 mg per day; May increase dose to 100 mg 2 to 3 times Yes Hospitalized patients a day by the end of the first week.
    [Show full text]